{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016815","form_type":"8-K/A","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2025-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.523671+00:00","generated_at":"2026-05-18T17:09:54.362214+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ProPhase Labs enters $1M bridge loan (20% OID) from CEO and investor; issues warrants","bullets":["Each loan (CEO and investor) $500k principal, 20% OID ($625k face), 10% interest, 12-month maturity.","Company issued 500,000 unvested warrants per loan (1M total) at $0.60/share, vesting conditional on shareholder approval.","Loans secured but subordinate to up to $6M senior debt; proceeds for working capital; repayment via Nebula Genomics sale or Crown Medical collections.","CEO loan is related-party transaction; Audit Committee approved; Karkus receives $10,000 expense reimbursement."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016815","json":"https://secwatch.observer/filing/0001641172-25-016815.json","markdown":"https://secwatch.observer/filing/0001641172-25-016815.md","text":"https://secwatch.observer/filing/0001641172-25-016815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000164117225016815/0001641172-25-016815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000164117225016815/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:09:54.362214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f263af8db828107c65c6f136f989cadf8a4a5076","claim":"ProPhase Labs, Inc. incurred loan of $500,000 with Ted Karkus and an unaffiliated investor at 10% maturing twelve (12) months from the execution date.","evidence_excerpt":"the Loan Agreement constitutes a related party transaction under Item 404(a) of Regulation S-K. The material terms of the loan are a non-convertible loan in the amount of $500,000, with a 20% original issue discount. The loan bears interest at an annual rate of 10% and matures twelve (12) months from the execution date. The Company will pay Mr. Karkus a","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000164117225016815/0001641172-25-016815-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Ted Karkus and an unaffiliated investor"},{"label":"Rate","value":"10%"},{"label":"Maturity","value":"twelve (12) months from the execution date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}